Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SinoBiomed To Conduct Clinical Trials In Thailand For China’s First Malaria Vaccine

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - SinoBiomed will conduct Phase IIb clinical trials of its recombinant malaria vaccine in Thailand in cooperation with Bangkok-based Mahidol University, the company announced Aug. 20

You may also be interested in...



Interpol Seizes Counterfeit Drugs In Southeast Asia; More Measures Mulled

The International Criminal Police Organization confiscated $6.65 million worth of counterfeit HIV/AIDS, malaria and tuberculosis drugs in Southeast Asia, the organization announced at the International Law Enforcement Training Seminar on Combating Counterfeit Drugs Nov. 17 in Phnom Penh, Cambodia

Interpol Seizes Counterfeit Drugs In Southeast Asia; More Measures Mulled

The International Criminal Police Organization confiscated $6.65 million worth of counterfeit HIV/AIDS, malaria and tuberculosis drugs in Southeast Asia, the organization announced at the International Law Enforcement Training Seminar on Combating Counterfeit Drugs Nov. 17 in Phnom Penh, Cambodia

Novartis Partners With Clinton Foundation, Indian And Chinese Drug Makers To Improve Access To Malaria Drugs

MUMBAI - Novartis and the Clinton Foundation have entered into agreements with six Indian and Chinese companies with the objective of lowering the price of malaria drugs and thereby improving access for patients in the developing and underdeveloped world

Related Content

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel